Ignite Creation Date:
2024-05-06 @ 3:47 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04755322
Status:
COMPLETED
Last Update Posted:
2023-12-08
First Post:
2021-02-11
Brief Title:
Hydroxychloroquine in Prevention of Preeclampsia
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Hydroxychloroquine is an Immunomodulator for Improvement of Pregnancy Outcomes in Preeclampsia
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pre-eclampsia complicates up to 8 of pregnancies and is a major contributor to maternal mortality and morbidity The only effective treatment is delivery which leads to significant neonatal morbidity and mortality if carried out preterm especially when the disease occurs early in pregnancy Vascular endothelial dysfunction and immunological impairment are associated with preeclampsia To date there is no effective or optimal therapeutic approach for these conditions Hydroxychloroquine has endothelial protective action via ant diabetic lipid lowering antioxidant effects or direct endothelial protection Hydroxychloroquine is an antimalarial and immunomodulatory agent In pregnancy hydroxychloroquine is prescribed for inflammatory conditions associated with adverse perinatal outcomes such as systemic lupus erythematosus antiphospholipid syndrome and placental inflammatory lesions such as chronic histiocytic intervillositis hydroxychloroquine has therapeutic potential to improve placental function in pregnancies associated with heightened inflammation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None